mirtazapine has been researched along with Depressive Disorder, Treatment-Resistant in 7 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Depressive Disorder, Treatment-Resistant: Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies. (Campbell's Psychiatric Dictionary, 9th ed.)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we report the case of a 20-year-old man with severe social anxiety disorder, major depressive disorder, insomnia and attenuated psychotic symptoms despite ongoing treatment with cognitive behavioural therapy and mirtazapine who was treated with adjunctive cannabidiol (CBD) in doses between 200 and 800 mg/day for 6 months." | 7.96 | Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. ( Amminger, GP; Berger, M; Li, E, 2020) |
| " Here, we report the case of a 20-year-old man with severe social anxiety disorder, major depressive disorder, insomnia and attenuated psychotic symptoms despite ongoing treatment with cognitive behavioural therapy and mirtazapine who was treated with adjunctive cannabidiol (CBD) in doses between 200 and 800 mg/day for 6 months." | 3.96 | Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. ( Amminger, GP; Berger, M; Li, E, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, M | 1 |
| Li, E | 1 |
| Amminger, GP | 1 |
| Rifkin-Zybutz, R | 1 |
| MacNeill, S | 2 |
| Davies, SJ | 1 |
| Dickens, C | 2 |
| Campbell, J | 3 |
| Anderson, IM | 2 |
| Chew-Graham, CA | 2 |
| Peters, TJ | 3 |
| Lewis, G | 3 |
| Wiles, N | 2 |
| Kessler, D | 2 |
| Kessler, DS | 1 |
| MacNeill, SJ | 1 |
| Tallon, D | 2 |
| Hollingworth, W | 2 |
| Round, J | 2 |
| Burns, A | 2 |
| Shepherd, T | 1 |
| Dickens, CM | 1 |
| Carter, M | 1 |
| Jenkinson, C | 1 |
| Macleod, U | 2 |
| Gibson, H | 1 |
| Davies, S | 2 |
| Wiles, NJ | 1 |
| Chew-Graham, C | 1 |
| Anderson, I | 1 |
| Gilbody, S | 1 |
| Zeeh, J | 1 |
| Simon, GE | 1 |
| Rzezniczek, S | 1 |
| Obuchowicz, M | 1 |
| Datka, W | 1 |
| Siwek, M | 1 |
| Dudek, D | 1 |
| Kmiotek, K | 1 |
| Oved, K | 1 |
| Shomron, N | 1 |
| Gurwitz, D | 1 |
| Pilc, A | 1 |
3 trials available for mirtazapine and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Does anxiety moderate the effectiveness of mirtazapine in patients with treatment-resistant depression? A secondary analysis of the MIR trial.
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Comorbidity; Data Interpretation, Statistical; | 2020 |
Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR).
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Drug Thera | 2018 |
Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
Topics: Adult; Aged; Antidepressive Agents; Cost-Benefit Analysis; Depressive Disorder, Treatment-Resistant; | 2018 |
4 other studies available for mirtazapine and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol.
Topics: Adult; Cannabidiol; Cognitive Behavioral Therapy; Depressive Disorder, Major; Depressive Disorder, T | 2020 |
Topics: Depressive Disorder, Treatment-Resistant; Humans; Mirtazapine; Primary Health Care; Selective Seroto | 2018 |
Adding mirtazapine to ongoing SNRIs or SSRIs did not improve symptoms of treatment-resistant depression.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Mirtazapine; Primary Health Care; Sele | 2019 |
Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients.
Topics: Adult; Biomarkers; Cell Proliferation; Depressive Disorder, Major; Depressive Disorder, Treatment-Re | 2016 |